Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Vertex, J&J Hepatitis C Drug Gets European Union Nod

September 22, 2011

After winning US approval in May, the new hepatitis C virus treatment telaprevir has been OK'd by EU regulators, Vertex Pharmaceuticals and Johnson & Johnson said Tuesday. J&J has European rights to the drug; Vertex, which holds exclusive US rights, will receive European royalties. The action was anticipated, given that the European Medicines Agency recommended approval in July. Sold under the brand name Incivek in the United States, telaprevir will be branded as Incivo in Europe. In studies, telaprevir administered with standard HCV treatment nearly doubled the cure rate achieved by standard treatment alone.

Back to other news for September 2011

Adapted from:
Reuters
09.20.2011; Anand Basu

  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

 

Advertisement